Company to Report Interim Celgosivir 4-Week Viral Kinetics Study Data on
Monday December 3, 2007
VANCOUVER and SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, December 13, 2007 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the second fiscal quarter ended October 31, 2007 and provide an update on company activities. To participate in the conference call, please dial 416-644-3418 or 1-800-732-1073. The call will be available for replay until December 27, 2007 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21255722 (followed by the number sign). The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.
Additionally, the Company will report interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2007.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the
area of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II
and preclinical), the prevention of catheter-related infections (Phase III)
and the treatment of dermatological diseases (Phase II). MIGENIX is
headquartered in Vancouver, British Columbia, Canada with US operations in
San Diego, California. Additional information can be found at
James M. DeMesa, M.D.
President & CEO
CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233,
|SOURCE MIGENIX Inc.|
Copyright©2007 PR Newswire.
All rights reserved